[go: up one dir, main page]

MA33813B1 - Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire - Google Patents

Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire

Info

Publication number
MA33813B1
MA33813B1 MA34956A MA34956A MA33813B1 MA 33813 B1 MA33813 B1 MA 33813B1 MA 34956 A MA34956 A MA 34956A MA 34956 A MA34956 A MA 34956A MA 33813 B1 MA33813 B1 MA 33813B1
Authority
MA
Morocco
Prior art keywords
diagnosis
source
parasitic disease
vaccine
parasitic
Prior art date
Application number
MA34956A
Other languages
Arabic (ar)
English (en)
Inventor
Garcia Laura Ramirez
Carlos Alonso-Bedate
Alvarez Manuel Soto
Original Assignee
Leti Sl Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leti Sl Lab filed Critical Leti Sl Lab
Publication of MA33813B1 publication Critical patent/MA33813B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur une composition comprenant une source de l3 et/ou de l5, et, facultativement, un adjuvant, pour la préparation d'un médicament pour le traitement ou la prévention d'une maladie parasitaire et sur son utilisation au diagnostic de ladite maladie parasitaire.
MA34956A 2009-11-13 2012-06-11 Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire MA33813B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26102009P 2009-11-13 2009-11-13
EP09175929 2009-11-13
PCT/EP2010/067380 WO2011058137A1 (fr) 2009-11-13 2010-11-12 Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire

Publications (1)

Publication Number Publication Date
MA33813B1 true MA33813B1 (fr) 2012-12-03

Family

ID=42060726

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34956A MA33813B1 (fr) 2009-11-13 2012-06-11 Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire

Country Status (26)

Country Link
US (1) US10604551B2 (fr)
EP (2) EP3101028A1 (fr)
JP (1) JP5875987B2 (fr)
KR (1) KR101881947B1 (fr)
CN (2) CN107551264B (fr)
AP (1) AP3464A (fr)
AR (1) AR080621A1 (fr)
AU (1) AU2010317962B2 (fr)
BR (1) BR112012011395B1 (fr)
CA (1) CA2780740C (fr)
CO (1) CO6551684A2 (fr)
CY (1) CY1118402T1 (fr)
EA (1) EA022221B1 (fr)
EC (1) ECSP12011951A (fr)
ES (1) ES2612786T3 (fr)
HR (1) HRP20170176T1 (fr)
IL (1) IL219770A (fr)
MA (1) MA33813B1 (fr)
MX (1) MX341066B (fr)
PE (1) PE20121553A1 (fr)
PH (1) PH12012500942A1 (fr)
PT (1) PT2499158T (fr)
SA (1) SA110310855B1 (fr)
TN (1) TN2012000217A1 (fr)
WO (1) WO2011058137A1 (fr)
ZA (1) ZA201203516B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
PL2638062T3 (pl) * 2010-11-10 2018-11-30 Laboratorios Leti, S.L. Nowy adiuwant
CN103796675B (zh) * 2011-05-09 2019-05-14 热体实验室有限公司 用于治疗炎症性疾病的分子
WO2015001383A1 (fr) * 2013-07-02 2015-01-08 Institut De Recherche Pour Le Developpement Peptides et procédés pour la détection de la leishmaniose
US10973897B2 (en) * 2016-04-14 2021-04-13 Peptcell Limited Chagas antigens and antibodies and compositions, methods and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
EP0893507A1 (fr) 1997-07-25 1999-01-27 Institut Gustave Roussy Utilisation de ligands de MHC classe II (CD4 et LAG-3) comme adjuvants pour la vaccination de LAG-3 dans le traitement du cancer
EP1009382B1 (fr) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Emulsions huile-dans-l'eau contenant des saponines
DE69940793D1 (de) 1998-12-23 2009-06-04 Leti Sl Lab Chimärisches Gen, dass für die antigenischen Determinanten von vier Proteinen aus L. Infantum kodiert
FR2826018B1 (fr) * 2001-06-18 2005-01-07 Pasteur Institut Tunis Gene associe a la virulence du parasite leishmania
US20050250716A1 (en) 2001-12-07 2005-11-10 Intercell Ag Immunostimulatory oligodeoxynucleotides
DE602004028000D1 (de) 2003-04-23 2010-08-19 Max Planck Gesellschaft Tuberkulose vaccine mit verbesserter effizienz
KR100992646B1 (ko) 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 파장판
WO2005044301A2 (fr) 2003-11-05 2005-05-19 C.B.F. Leti, S.L. Unipersonal Application d'histones specifiques au traitement de maladies parasitaires
CA2540736A1 (fr) * 2005-04-08 2006-10-08 Institut Pasteur Polypeptides de leishmania major et polynucleotides les encodant, applications vaccinales, therapeutiques et diagnostiques de ceux-ci
CN101466831A (zh) * 2006-04-10 2009-06-24 传染病研究所有限公司 用于诊断和治疗利什曼病的化合物和方法
WO2009012166A1 (fr) * 2007-07-13 2009-01-22 Infectious Disease Research Institute Compositions de stérol 24-c-méthyltransférase de leishmania pour la prévention, le traitement et le diagnostic de leishmanioses
PT2231700E (pt) 2008-01-18 2014-07-31 Leti S L Unipersonal Lab Vacina que compreende extrato de proteína ribossomal (rpe) e um auxiliar estimulante th1 como opção
BR112012000679A2 (pt) * 2009-07-13 2016-11-01 Leti Sl Lab diagnóstico de uma doença parasitária como a leishmaniose utilizando um extrato de proteína ribossômica (epr)
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي

Also Published As

Publication number Publication date
EP2499158B1 (fr) 2016-11-02
ES2612786T3 (es) 2017-05-18
HK1176074A1 (en) 2013-07-19
US10604551B2 (en) 2020-03-31
PT2499158T (pt) 2017-01-24
AP3464A (en) 2015-11-30
HRP20170176T1 (hr) 2017-04-07
IL219770A0 (en) 2012-07-31
CN107551264A (zh) 2018-01-09
IL219770A (en) 2017-10-31
AR080621A1 (es) 2012-04-25
PH12012500942A1 (en) 2013-01-07
JP2013510823A (ja) 2013-03-28
EA022221B1 (ru) 2015-11-30
JP5875987B2 (ja) 2016-03-02
EP3101028A1 (fr) 2016-12-07
EP2499158A1 (fr) 2012-09-19
MX2012005522A (es) 2012-09-28
CA2780740A1 (fr) 2011-05-19
AU2010317962B2 (en) 2014-09-18
SA110310855B1 (ar) 2014-09-16
BR112012011395B1 (pt) 2022-03-03
CN102712684A (zh) 2012-10-03
BR112012011395A2 (pt) 2020-09-01
CY1118402T1 (el) 2017-06-28
US20120263746A1 (en) 2012-10-18
KR20120104567A (ko) 2012-09-21
MX341066B (es) 2016-08-05
WO2011058137A1 (fr) 2011-05-19
ECSP12011951A (es) 2012-07-31
AP2012006275A0 (en) 2012-06-30
KR101881947B1 (ko) 2018-07-26
PE20121553A1 (es) 2012-12-13
CO6551684A2 (es) 2012-10-31
EA201290319A1 (ru) 2012-12-28
TN2012000217A1 (en) 2013-12-12
CN107551264B (zh) 2021-05-11
CA2780740C (fr) 2019-08-20
AU2010317962A1 (en) 2012-06-21
ZA201203516B (en) 2013-01-31

Similar Documents

Publication Publication Date Title
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
WO2009126688A8 (fr) Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire
WO2011110655A3 (fr) Vaccin
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
EP2987807A3 (fr) Anticorps dirigés contre tau phosphorylée
MX375202B (es) Composiciones adyuvantes novedosas.
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112012018386A8 (pt) "inibidores isoindolinona de fosfatidilinositol 3-quinase"
EP3219725A3 (fr) Anticorps dkk1 et procédés d'utilisation
MX2010008468A (es) Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
EA201290171A1 (ru) Вводимые перорально кортикостероидные композиции
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MA34057B1 (fr) Compositions et methodes pour le diagnostic et le traitement d'une tumeur
WO2011026125A3 (fr) Compositions pharmaceutiques à rétention gastrique permettant une libération immédiate et prolongée d'acétaminophène
EP3590532C0 (fr) Vaccin pour la prévention ou le traitement d'une maladie de voies respiratoires d'origine allergique
IT1396017B1 (it) Dispositivo medico per l'applicazione di cateteri, particolarmente per procedure di toracentesi.
WO2010135521A3 (fr) Compositions et procédés pour le traitement et le diagnostic de la grippe
MA33813B1 (fr) Utilisation d'une source de l3 et/ou de l5 comme vaccin ou comme diagnostic pour une maladie parasitaire
EP2640408A4 (fr) Compositions kératiniques pour le traitement d'une déficience ou lésion osseuse
BR112012013199A2 (pt) composto, composição farmacêutica, e , uso de um composto
WO2011112670A3 (fr) Procédés et compositions pour antigènes de chlamydia dans le diagnostic et le traitement d'infections et de maladies à chlamydia
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
BRPI1003940B8 (pt) Composição para cuidado de saúde compreendendo um tensoativo polimerizado de baixo dp e um espessante micelar
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical